Identification

Name
Haloperidol
Accession Number
DB00502  (APRD00538)
Type
Small Molecule
Groups
Approved
Description

A phenyl-piperidinyl-butyrophenone, traditional antipsychotic drug that is used primarily to treat schizophrenia and other psychoses. It is also used for the management of schizoaffective disorder, delusional disorders, ballism, and Tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea associated with Huntington's disease. It is a potent antiemetic and is used in the treatment of intractable hiccups [5], [7].

The efficacy of haloperidol was first established in controlled trials in the 1960s [9].

Interestingly, in vivo pharmacogenetic studies have demonstrated that the metabolism of haloperidol may be modulated by genetically determined polymorphic CYP2D6 activity. However, these findings contradict the findings from studies in vitro with human liver microsomes and from drug interaction studies in vivo. Inter-ethnic and pharmacogenetic differences in haloperidol metabolism may possibly explain these observations [3].

Structure
Thumb
Synonyms
  • 1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine
  • 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
  • 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
  • 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
  • 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
  • Haloperidolum
  • γ-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone
External IDs
MCN-JR-1625 / NSC-170973 / NSC-615296 / R-1625
Product Ingredients
IngredientUNIICASInChI Key
Haloperidol decanoateAC20PJ410174050-97-8GUTXTARXLVFHDK-UHFFFAOYSA-N
Haloperidol lactate6387S86PK353515-91-6BVUSNQJCSYDJJG-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Haloperidol Liq 2mg/mlSolution2 mgOralApotex Corporation1983-12-31Not applicableCanada
Apo Haloperidol Tab 0.5mgTablet.5 mgOralApotex Corporation1980-12-31Not applicableCanada
Apo Haloperidol Tab 1mgTablet1 mgOralApotex Corporation1980-12-31Not applicableCanada
HaldolInjection5 mg/mLIntramuscularJanssen Pharmaceuticals1971-05-18Not applicableUs
Haldol DecanoateInjection100 mg/mLIntramuscularJanssen Pharmaceuticals1986-01-14Not applicableUs
Haldol DecanoateInjection50 mg/mLIntramuscularJanssen Pharmaceuticals1986-01-14Not applicableUs
Haldol Injection 5mg/mlLiquid5 mgIntramuscularMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1966-12-312006-08-04Canada
Haldol LA Inj 100mg/mlLiquid100 mgIntramuscularJanssen Pharmaceuticals1983-12-312006-08-04Canada
Haldol LA Inj 50mg/mlLiquid50 mgIntramuscularJanssen Pharmaceuticals1983-12-312006-01-23Canada
Haloperidol Decanoate Inj. Liq Im 100mg/mlLiquid100 mgIntramuscularDavid Bull Laboratories (Pty) Ltd.1995-12-311998-08-13Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-haloperidol LA InjectableLiquid100 mgIntramuscularApotex Corporation2000-06-302013-08-02Canada
Apo-haloperidol LA InjectableLiquid50 mgIntramuscularApotex Corporation2000-06-302013-08-02Canada
Apo-haloperidol Tab 10mgTablet10 mgOralApotex Corporation1987-12-31Not applicableCanada
Apo-haloperidol Tab 2mgTablet2 mgOralApotex Corporation1987-12-31Not applicableCanada
Apo-haloperidol Tab 5mgTablet5 mgOralApotex Corporation1987-12-31Not applicableCanada
HaloperidolTablet10 mg/1OralClinical Solutions Wholsesale1988-03-11Not applicableUs
HaloperidolTablet1 mg/1OralRemedy Repack2007-04-23Not applicableUs
HaloperidolTablet1 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1986-11-172018-05-11Us
HaloperidolTablet5 mg/1OralMc Kesson Contract Packaging2013-04-102018-05-15Us
HaloperidolInjection5 mg/mLIntramuscularTYA Pharmaceuticals2011-06-17Not applicableUs
International/Other Brands
Aloperidin (Janssen-Cilag) / Bioperidolo (Firma) / Brotopon (Pfizer) / Dozic (Rosemont) / Duraperidol / Einalon S / Eukystol (Merckle) / Halosten (Shionogi Seiyaku) / Keselan (Sumitomo) / Linton (Tanabe Mitsubishi Pharma) / Peluces (lsei) / Serenace (Pfizer) / Sigaperidol (Siegfried)
Categories
UNII
J6292F8L3D
CAS number
52-86-8
Weight
Average: 375.864
Monoisotopic: 375.140134897
Chemical Formula
C21H23ClFNO2
InChI Key
LNEPOXFFQSENCJ-UHFFFAOYSA-N
InChI
InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
IUPAC Name
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
SMILES
OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1

Pharmacology

Indication

For the treatment of schizophrenia [10]

For the treatment of acute psychosis in acutely agitated schizophrenic patients with moderately severe to very severe symptoms [10]

For the treatment of severe behavioral or psychological symptoms of dementia [10]

For the treatment of delirium in the pediatric intensive care unit [10]

For the treatment of agitation or delirium [10]

For agitation† or delirium in adult patients with no underlying psychiatric illness [10]

For use as a second-line agent for rescue treatment of chemotherapy-induced nausea/vomiting [10]

For the treatment of irritability associated with autistic disorder [10]

For the treatment of tics and vocal utterances associated with Tourette's syndrome [10]

For the treatment of severe behavioral problems associated with oppositional defiant disorder or other disruptive behavioral disorders, or for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients who show excessive motor activity with accompanying conduct disorders [10]

Associated Conditions
Pharmacodynamics

Haloperidol is a psychotropic agent. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on several organ systems. Haloperidol has potent neuroleptic antiadrenergic activity and weak peripheral anticholinergic activity, as well as minor ganglionic binding ability. It also possesses slight antihistaminic and anti-serotonergic activity and may also act as an anti-emetic [7].

Mechanism of action

Haloperidol inhibits the effects of dopamine and increases its turnover, however, the exact mechanism of action is not fully understood [Label]. Dopamine overactivity can be presynaptic (an excess of dopamine release from dopamine nerve terminals) or post-synaptic (an increase in the density of D2 receptors or an increase in post-receptor action) [11]. Traditional antipsychotics, such as haloperidol, bind more tightly than dopamine itself to the dopamine D2 receptor, with dissociation constants that are lower than that for dopamine [4].

It is believed that haloperidol competitively blocks post-synaptic dopamine (D2) receptors in the brain, eliminating dopamine neurotransmission and leading to the relief of delusions and hallucinations that are commonly associated with psychosis. It acts primarily on the D2-receptors and has some effect on 5-HT2 and α1-receptors, with negligible effects on dopamine D1-receptors. The drug also exerts some blockade of α-adrenergic receptors of the autonomic system [14].

Antagonistic activity regulated through dopamine D2 receptors in the chemoreceptive trigger zone (CTZ) of the brain renders its antiemetic activity [7]. Of the three D2-like receptors, only the D2 receptor is blocked by antipsychotic drugs in direct relation to their clinical antipsychotic abilities. The optimal clinical efficacy of antipsychotics is associated with the blockade of approximately 60 % - 80 % of D2 receptors in the brain [12].

Clinical brain-imaging findings show that haloperidol remains tightly bound to D2 dopamine receptors in humans undergoing 2 positron emission tomography (PET) scans with a 24h pause in between scans [4]. A common adverse effect of this drug is the development of extrapyramidal symptoms (EPS), due to the tight binding of haloperidol to the dopamine D2 receptor [Label]. Further information is found in the "Toxicity" section of this drug profile.

Due to the risk of unpleasant and sometimes lifelong extrapyramidal symptoms, newer antipsychotic medications than haloperidol have been discovered and formulated. Rapid dissociation of drugs from dopamine D2 receptors is a plausible explanation for the improved EPS profile of atypical antipsychotics such as Risperidone. This is also consistent with the theory of a lower affinity for D2 receptors for these drugs [12]. As mentioned above, haloperidol binds tightly to the dopamine receptor, potentiating the risk of extrapyramidal symptoms [4], and therefore should only been used when necessary.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UGlutamate receptor ionotropic, NMDA 2B
antagonist
Human
U5-hydroxytryptamine receptor 2A
other/unknown
Human
UD(3) dopamine receptor
inverse agonist
Human
UMelanin-concentrating hormone receptor 1Not AvailableHuman
USynaptic vesicular amine transporterNot AvailableHuman
Absorption

Haloperidol is well-absorbed from the gastrointestinal tract when ingested orally, however, the first-pass hepatic metabolism decreases its oral bioavailability to 40 - 75% [7].

Administration of haloperidol decanoate (the depot form of haloperidol for long-term treatment) in sesame oil results in slow release of the drug for long-term effects. The plasma concentrations of haloperidol gradually rise, reaching its peak concentration at about 6 days after the injection, with an apparent half-life of about 21 days. Steady-state plasma concentrations are achieved after the third or fourth dose [Label].

Serum concentration peaks 0.5 to 4 hours after an oral dose [7].

Volume of distribution

The apparent volume of distribution is about 20 L/kg, in concordance with the high lipophilicity of the drug [7], and largely depends on the subject [17].

Haloperidol is rapidly distributed to various tissues and organs, as indicated by the large volume of distribution (mean values 8 to 21 L/kg after intravenous dosing). Haloperidol readily crosses the blood-brain barrier. It also crosses the placenta and is excreted in breast milk [17].

Protein binding

Haloperidol circulates in the blood bound predominantly (90-94%) to plasma proteins [7].

Metabolism

Its metabolic fate has not been clearly established, it appears that haloperidol is primarily metabolized in the liver [7].

The drug is thought to be metabolized primarily by oxidative N-dealkylation of the piperidine nitrogen to form fluorophenylcarbonic acids and piperidine metabolites (which appear to be inactive), and by reduction of the butyrophenone carbonyl to the carbinol, forming hydroxyhaloperidol.

Some data suggest that the reduced metabolite, hydroxyhaloperidol, has some pharmacologic activity, although its activity appears to be inferior to that of haloperidol. Urinary metabolites in rats include p-fluorophenaceturic acid, beta-p-fluorobenzoylpropionic acid, and several unidentified acids [7].

The enzymes involved in the biotransformation of haloperidol include cytochrome P450 (CYP), carbonyl reductase and uridine di-phosphoglucose glucuronosyltransferase enzymes. The greatest proportion of the intrinsic hepatic clearance of haloperidol is performed by glucuronidation and followed by the reduction of haloperidol to reduced haloperidol and by CYP-mediated oxidation.

In studies of cytochrome-mediated disposition in vitro, CYP3A4 appears to be the major isoform of the enzyme responsible for the metabolism of haloperidol in humans. The intrinsic clearance of the back-oxidation of reduced haloperidol to the parent compound, oxidative N-dealkylation and pyridinium formation are of the same order of magnitude. This suggests that the same enzyme system is responsible for the above three metabolic reactions [7].

Haloperidol is a substrate of CYP3A4 and an inhibitor, as well as a stimulator, of CYP2D6 [7].

Route of elimination

Urine 40% (1% unchanged), feces 15% [8]

Half life

For the non-decanoate formulations, the haloperidol half-life is on average 24 hours after oral administration and 21 hours after intramuscular administration [17].

Clearance

Haloperidol clearance after extravascular administration ranges from 0.9-1.5 l/h/kg, however this rate is reduced in poor metabolizers of CYP2D6 enzyme. Reduced CYP2D6 enzyme activity may result in increased concentrations of haloperidol. The inter-subject variability (coefficient of variation, %) in haloperidol clearance was estimated to be 44% in a population pharmacokinetic analysis in patients with schizophrenia [17].

Toxicity

Acute oral toxicity (LD50): 71 mg/kg in rats [MSDS].

Toxicity of haloperidol may be divided into several categories, according the FDA label:

Cardiovascular Effects

The incidence of sudden death, QT-prolongation, and Torsades de Pointes has been reported in patients treated with this drug. Higher than usual doses of any formulation and intravenous (IV) administration of haloperidol have shown to be associated with a higher risk of QT-prolongation and Torsades de Pointes [Label].

Caution is advised in treating patients with other cardiac QT-prolonging conditions (including electrolyte imbalance [particularly hypokalemia and hypomagnesemia], drugs which prolong the QT interval, underlying cardiac abnormalities, hypothyroidism, and familial long QT-syndrome). Depot haloperidol is not to be administered by the IV route [Label].

Extrapyramidal Symptoms

Extrapyramidal symptoms are comprised of a group of movement disorders which may include dystonia, akathisia, tardive dyskinesia and parkinsonism. Drug-induced extrapyramidal symptoms have been common knowledge for decades, yet the use of these drugs is still common. Despite this, these symptoms may prove to be long-lasting, and therefore, caution is warranted in the prevention of extrapyramidal symptoms [13].

Tardive Dyskinesia

This is a consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs and is known as an extrapyramidal symptom [Label]. Although the prevalence of the syndrome appears to be high among the elderly, this is a particularly common occurrence in elderly women [Label]

The risk of developing tardive dyskinesia and the risk that it may be irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient over time. However, the syndrome can develop, although much less commonly, after brief periods of treatment at lower doses [Label].

There are no known treatments for established cases of tardive dyskinesia. The syndrome may remit, partially or completely, if antipsychotic treatment is removed [Label].

Antipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. However, some patients may require treatment despite the presence of the syndrome [Label].

Neuroleptic Malignant Syndrome (NMS)

A potentially fatal condition, sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been demonstrated in association with antipsychotic drugs treatment. Clinical signs and symptoms of NMS are hyperpyrexia, muscle rigidity, alterations in mental status (including catatonia) and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Other signs include elevated creatine phosphokinase (CPK), myoglobinuria (rhabdomyolysis) and acute kidney failure [Label].

General

In addition to the above toxicities, number of cases of bronchopneumonia, some fatal, have followed the use of antipsychotic drugs, including haloperidol. One theory suggests that lethargy and decreased sensation of thirst due to central inhibition may lead to dehydration, hemoconcentration and reduced pulmonary ventilation. Therefore, if the above signs and symptoms appear, especially in the elderly, the physician should institute remedial therapy promptly.

Hematologic Effects

Reports have been made of the occurrence of mild, usually transient leukopenia and leukocytosis, minimal decreases in red blood cell counts, anemia, or a tendency toward monocytosis. Agranulocytosis has rarely been reported to have occurred with the use of haloperidol, and then only in association with other medication [Label].

Liver Effects

Impaired liver function and/or jaundice may occur.

Dermatologic Reactions

Maculopapular and acne-like skin reactions and isolated cases of photosensitivity and loss of hair.

Endocrine Disorders

Lactation, breast engorgement, mastalgia, menstrual irregularities, gynecomastia, impotence, increased libido, hyperglycemia, hypoglycemia and hyponatremia [Label]

Gastrointestinal Effects

Anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea and vomiting [Label]

Autonomic Reactions

Dry mouth, blurred vision, urinary retention, diaphoresis and priapism [Label]

Respiratory Effects

Laryngospasm, bronchospasm and increased depth of respiration [Label]

Special Senses

Cataracts, retinopathy and visual disturbances [Label]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Haloperidol.Investigational
2,5-Dimethoxy-4-ethylamphetamineHaloperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineHaloperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineHaloperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineHaloperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Haloperidol.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Haloperidol is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Haloperidol can be increased when it is combined with Abiraterone.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Haloperidol.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Haloperidol.Approved, Experimental, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Haloperidol.Approved
Acetyl sulfisoxazoleThe metabolism of Haloperidol can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Haloperidol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Haloperidol.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Haloperidol.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Haloperidol.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Agomelatine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Haloperidol.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alaproclate.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Haloperidol.Approved, Withdrawn
AlfaxaloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Allopregnanolone.Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Haloperidol.Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Haloperidol.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Haloperidol.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Haloperidol.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Haloperidol.Approved, Withdrawn
AmantadineThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Amantadine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Haloperidol.Approved, Withdrawn
AmiodaroneHaloperidol may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideHaloperidol may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Haloperidol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amobarbital.Approved, Illicit
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Haloperidol.Approved
AmperozideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Haloperidol.Approved, Illicit, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Haloperidol.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Haloperidol.Approved, Investigational
AnagrelideHaloperidol may increase the QTc-prolonging activities of Anagrelide.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Haloperidol.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Haloperidol.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Haloperidol.Approved, Investigational
ApalutamideThe serum concentration of Haloperidol can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Haloperidol.Investigational
ApomorphineThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Apomorphine.Approved, Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Haloperidol.Approved, Investigational
AprepitantThe serum concentration of Haloperidol can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Haloperidol.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Haloperidol.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
ArmodafinilThe metabolism of Haloperidol can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideHaloperidol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherHaloperidol may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Articaine.Approved
AsenapineHaloperidol may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Haloperidol.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Haloperidol.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Haloperidol can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Haloperidol can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Azaperone.Investigational, Vet Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Haloperidol.Withdrawn
AzelastineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Haloperidol.Approved
BaclofenThe risk or severity of adverse effects can be increased when Haloperidol is combined with Baclofen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Haloperidol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Barbital.Illicit
BedaquilineHaloperidol may increase the QTc-prolonging activities of Bedaquiline.Approved
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Haloperidol.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Haloperidol.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Haloperidol.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Benperidol.Approved, Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Haloperidol.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Benzocaine.Approved, Investigational
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Haloperidol.Approved, Investigational
BenzphetamineHaloperidol may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Haloperidol.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Haloperidol.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Haloperidol.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Haloperidol.Approved, Investigational
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Haloperidol.Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Haloperidol.Approved
BoceprevirThe metabolism of Haloperidol can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Haloperidol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Haloperidol can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Haloperidol.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Haloperidol.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Haloperidol.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Bromazepam.Approved, Illicit, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Haloperidol.Approved
BromisovalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Haloperidol.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Bromperidol.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Haloperidol.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Brotizolam.Approved, Investigational, Withdrawn
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Haloperidol.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Haloperidol.Approved, Experimental
BufuralolThe metabolism of Bufuralol can be decreased when combined with Haloperidol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Haloperidol.Experimental
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Haloperidol.Approved, Investigational
BuprenorphineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Haloperidol can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Haloperidol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Haloperidol.Approved
CaffeineThe metabolism of Haloperidol can be decreased when combined with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Haloperidol is combined with Canertinib.Investigational
CapecitabineThe metabolism of Haloperidol can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Haloperidol.Approved
CarbamazepineThe metabolism of Haloperidol can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Haloperidol.Experimental, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Haloperidol.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carisoprodol.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Haloperidol.Approved, Vet Approved, Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Haloperidol.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Haloperidol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Haloperidol.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Haloperidol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Haloperidol.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Haloperidol can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Haloperidol.Approved, Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Haloperidol.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Haloperidol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Haloperidol.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chloroprocaine.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Haloperidol.Approved, Investigational, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Haloperidol.Approved
ChlorphentermineHaloperidol may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Haloperidol.Approved
CholecalciferolThe metabolism of Haloperidol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Haloperidol.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Haloperidol.Approved, Investigational
CimetidineThe metabolism of Haloperidol can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Haloperidol can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Haloperidol.Approved, Investigational
CiprofloxacinHaloperidol may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideHaloperidol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramHaloperidol may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Haloperidol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Haloperidol can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Haloperidol.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clidinium.Approved
ClobazamThe metabolism of Haloperidol can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Haloperidol is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Haloperidol.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clonazepam.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Haloperidol.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Haloperidol.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Haloperidol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Haloperidol.Approved
CobicistatThe serum concentration of Haloperidol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Haloperidol can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Haloperidol.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Haloperidol.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Haloperidol.Approved, Investigational
CrisaboroleThe metabolism of Haloperidol can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibHaloperidol may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Haloperidol.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Haloperidol.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Haloperidol.Approved, Investigational
CyclopropaneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Haloperidol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Haloperidol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Haloperidol.Approved
DabrafenibThe serum concentration of Haloperidol can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dantrolene.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Haloperidol.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Haloperidol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Haloperidol can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Haloperidol.Approved
DasatinibThe serum concentration of Haloperidol can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Haloperidol.Approved, Investigational
DeferasiroxThe serum concentration of Haloperidol can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Haloperidol.Approved
DelamanidHaloperidol may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe metabolism of Haloperidol can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Desflurane.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Haloperidol.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Detomidine.Vet Approved
DeutetrabenazineHaloperidol may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dexbrompheniramine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Haloperidol.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Haloperidol.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Haloperidol.Approved, Investigational
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Haloperidol.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Haloperidol.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Haloperidol.Approved, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Haloperidol is combined with Diethyl ether.Experimental
DiethylpropionHaloperidol may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Difenoxin.Approved, Illicit
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Haloperidol.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Haloperidol.Approved, Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Haloperidol.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Haloperidol.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Haloperidol.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Haloperidol.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Haloperidol.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Haloperidol can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Haloperidol.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Diphenoxylate.Approved, Illicit
DisopyramideHaloperidol may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dixyrazine.Experimental
DofetilideHaloperidol may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronHaloperidol may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneHaloperidol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Haloperidol.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Haloperidol.Approved
DoramectinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Haloperidol can be decreased when combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Haloperidol.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Haloperidol.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Haloperidol.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Haloperidol.Approved, Investigational
DoxycyclineThe metabolism of Haloperidol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Haloperidol is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved, Illicit
DronedaroneHaloperidol may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Drotebanol.Experimental, Illicit
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Haloperidol.Withdrawn
DuloxetineThe metabolism of Haloperidol can be decreased when combined with Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Haloperidol.Investigational
DyclonineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dyclonine.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Haloperidol.Investigational
EcgonineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Haloperidol.Approved
EfavirenzThe metabolism of Haloperidol can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Haloperidol.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Haloperidol.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Eltanolone.Investigational
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Haloperidol.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Haloperidol.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Haloperidol.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Haloperidol can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Haloperidol.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Haloperidol.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Haloperidol.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Haloperidol.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Haloperidol.Approved
EribulinEribulin may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Haloperidol.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational, Vet Approved
EscitalopramHaloperidol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Haloperidol can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Haloperidol.Investigational
EsomeprazoleThe metabolism of Haloperidol can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Haloperidol.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Haloperidol.Approved, Investigational
EthanolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Haloperidol.Experimental
EthosuximideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Haloperidol.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etizolam.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Haloperidol.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Haloperidol.Approved, Investigational
EtomidateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etoperidone.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Haloperidol.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Haloperidol can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Haloperidol.Investigational, Nutraceutical
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Haloperidol.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Haloperidol.Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Haloperidol.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Haloperidol.Approved
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Haloperidol.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Haloperidol.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Haloperidol.Approved
FentanylThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Haloperidol.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Haloperidol.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Haloperidol.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Haloperidol.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fexofenadine.Approved, Investigational
FingolimodThe metabolism of Fingolimod can be decreased when combined with Haloperidol.Approved, Investigational
FlecainideHaloperidol may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flibanserin.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Haloperidol.Approved, Withdrawn
FloxuridineThe metabolism of Haloperidol can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Haloperidol can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Haloperidol.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flunitrazepam.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Haloperidol.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Haloperidol.Experimental
FluorouracilThe metabolism of Haloperidol can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
FlupentixolHaloperidol may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Haloperidol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flurazepam.Approved, Illicit, Investigational
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Haloperidol.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Haloperidol.Approved
FluvoxamineThe serum concentration of Haloperidol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Haloperidol.Approved, Investigational
FosamprenavirThe metabolism of Haloperidol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Haloperidol can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Haloperidol.Approved
FosphenytoinThe metabolism of Haloperidol can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Haloperidol.Approved, Investigational
Fusidic AcidThe serum concentration of Haloperidol can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gabapentin Enacarbil.Approved, Investigational
Gadobenic acidHaloperidol may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Haloperidol.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Haloperidol.Approved, Investigational
GemfibrozilThe metabolism of Haloperidol can be decreased when combined with Gemfibrozil.Approved
GemifloxacinHaloperidol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineHaloperidol may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Glutethimide.Approved, Illicit
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Haloperidol.Approved
GlycopyrroniumThe serum concentration of Haloperidol can be decreased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Haloperidol.Approved
GranisetronHaloperidol may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Haloperidol.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Haloperidol.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Hexobarbital.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Haloperidol.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Haloperidol.Approved
HydrocodoneHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Haloperidol.Approved, Illicit
HydroxyamphetamineHaloperidol may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Haloperidol.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Haloperidol.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Haloperidol.Withdrawn
IbutilideHaloperidol may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Haloperidol.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Haloperidol.Approved
IdelalisibThe metabolism of Haloperidol can be decreased when combined with Idelalisib.Approved
IloperidoneHaloperidol may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Haloperidol can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Haloperidol.Experimental
ImipramineThe metabolism of Imipramine can be decreased when combined with Haloperidol.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Haloperidol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Haloperidol.Approved
IndinavirThe metabolism of Haloperidol can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Indiplon.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Haloperidol.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Haloperidol.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Haloperidol.Withdrawn
Iofetamine I-123Haloperidol may decrease the stimulatory activities of Iofetamine I-123.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Haloperidol.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium bromide can be decreased when combined with Haloperidol.Approved
IrbesartanThe metabolism of Haloperidol can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Haloperidol can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Haloperidol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Haloperidol can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Haloperidol can be decreased when combined with Isoniazid.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Haloperidol.Withdrawn
IsradipineThe metabolism of Haloperidol can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Haloperidol can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Haloperidol.Approved
IvacaftorThe serum concentration of Haloperidol can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Haloperidol.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Haloperidol.Experimental
KetamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Haloperidol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Haloperidol.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Haloperidol.Approved
LabetalolThe metabolism of Labetalol can be decreased when combined with Haloperidol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lamotrigine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Haloperidol.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Haloperidol.Approved, Investigational
LenvatinibHaloperidol may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Haloperidol.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Levodopa.Approved
LevofloxacinHaloperidol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Haloperidol.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levorphanol.Approved
LidocaineThe metabolism of Haloperidol can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Haloperidol.Approved, Investigational
LisdexamfetamineHaloperidol may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Haloperidol.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Haloperidol.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Haloperidol.Experimental
LobeglitazoneThe metabolism of Haloperidol can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Haloperidol can be increased when used in combination with Lofexidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Haloperidol.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Haloperidol.Experimental
LoperamideThe metabolism of Loperamide can be decreased when combined with Haloperidol.Approved
LopinavirHaloperidol may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Loprazolam.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Haloperidol.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Haloperidol.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lormetazepam.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Haloperidol.Approved, Investigational
LorpiprazoleThe serum concentration of Haloperidol can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Haloperidol can be decreased when combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Haloperidol.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Haloperidol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Haloperidol.Approved, Investigational
LuliconazoleThe serum concentration of Haloperidol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Haloperidol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineHaloperidol may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Haloperidol.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lurasidone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Haloperidol.Illicit, Investigational, Withdrawn
MacimorelinHaloperidol may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Haloperidol.Approved
Magnesium sulfateThe therapeutic efficacy of Haloperidol can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Haloperidol can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Haloperidol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Haloperidol.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Haloperidol is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Meclizine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Haloperidol.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Medetomidine.Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Haloperidol.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Haloperidol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Haloperidol.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Melperone.Approved, Investigational
MemantineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Memantine.Approved, Investigational
MephedroneHaloperidol may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineHaloperidol may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Haloperidol.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Haloperidol.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Meptazinol.Experimental
MequitazineHaloperidol may increase the arrhythmogenic activities of Mequitazine.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Haloperidol.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Haloperidol.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Haloperidol.Approved, Investigational, Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Haloperidol.Experimental
MethadoneMethadone may increase the QTc-prolonging activities of Haloperidol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Haloperidol.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Haloperidol.Approved
MethotrimeprazineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Haloperidol.Approved, Investigational, Vet Approved
MethoxyphenamineHaloperidol may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylecgonine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Haloperidol.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenobarbital.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Haloperidol.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Haloperidol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.Approved, Investigational
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Haloperidol.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Haloperidol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Haloperidol.Approved
MetyrosineHaloperidol may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Haloperidol.Experimental
MexiletineThe metabolism of Haloperidol can be decreased when combined with Mexiletine.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Haloperidol.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Midazolam.Approved, Illicit
MidomafetamineHaloperidol may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Haloperidol can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
MifepristoneThe serum concentration of Haloperidol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Haloperidol is combined with Milnacipran.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Haloperidol.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Haloperidol.Approved
MirtazapineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Haloperidol can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Haloperidol.Investigational
MMDAHaloperidol may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Haloperidol.Approved, Investigational
ModafinilThe metabolism of Haloperidol can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Haloperidol.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Haloperidol.Experimental
MolindoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Molindone.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Haloperidol.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Haloperidol.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Haloperidol.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Haloperidol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Haloperidol.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Haloperidol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Haloperidol.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Haloperidol.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Haloperidol.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Haloperidol.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Haloperidol.Approved, Investigational
NefazodoneThe metabolism of Haloperidol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Haloperidol can be decreased when combined with Nelfinavir.Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Haloperidol.Approved, Investigational
NetupitantThe serum concentration of Haloperidol can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Haloperidol can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Haloperidol can be decreased when combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Haloperidol.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Haloperidol.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Haloperidol.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Haloperidol.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Haloperidol.Approved
NilotinibHaloperidol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Haloperidol.Approved, Investigational, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Haloperidol.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nitrazepam.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Haloperidol.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Haloperidol.Approved, Investigational, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nitrous oxide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nordazepam.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Haloperidol.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Haloperidol.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
OfloxacinHaloperidol may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Haloperidol.Approved, Investigational
OlaparibThe metabolism of Haloperidol can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Haloperidol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Haloperidol.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Haloperidol.Approved
OmeprazoleThe metabolism of Haloperidol can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronHaloperidol may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Haloperidol is combined with Opium.Approved, Illicit
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Haloperidol.Vet Approved
OrphenadrineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Haloperidol is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Haloperidol can be increased when it is combined with Osimertinib.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Haloperidol.Approved
OxazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxazepam.Approved
OxprenololThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Haloperidol.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Haloperidol.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Haloperidol.Approved, Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
PalbociclibThe serum concentration of Haloperidol can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneHaloperidol may increase the QTc-prolonging activities of Paliperidone.Approved
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Haloperidol.Experimental, Nutraceutical
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Haloperidol.Approved, Investigational
PanobinostatThe serum concentration of Haloperidol can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Haloperidol can be decreased when combined with Pantoprazole.Approved
ParaldehydeHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Haloperidol.Approved
ParoxetineThe metabolism of Haloperidol can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Haloperidol.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Haloperidol.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Haloperidol.Approved
Peginterferon alfa-2bThe serum concentration of Haloperidol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Penfluridol.Experimental
PentamidineHaloperidol may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Haloperidol can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
PerazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Perazine.Approved, Investigational
PerflutrenHaloperidol may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Haloperidol.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Haloperidol.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Haloperidol.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Haloperidol.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Haloperidol.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Haloperidol.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Haloperidol.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Haloperidol is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Haloperidol can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Phenoxyethanol.Approved
PhentermineHaloperidol may decrease the stimulatory activities of Phentermine.Approved, Illicit
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Haloperidol.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Haloperidol.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Haloperidol.Approved, Investigational
PhenytoinThe metabolism of Haloperidol can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Haloperidol.Approved, Investigational
PimozideHaloperidol may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Haloperidol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pipamperone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Haloperidol.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Haloperidol.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Haloperidol.Approved, Investigational
PiribedilThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Piritramide.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Haloperidol.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Haloperidol.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Haloperidol.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Haloperidol.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Haloperidol.Approved, Investigational
PosaconazoleThe metabolism of Haloperidol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleHaloperidol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pramocaine.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Haloperidol.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Haloperidol.Approved
PrazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Haloperidol can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Prilocaine.Approved
PrimaquineHaloperidol may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Haloperidol can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideHaloperidol may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Haloperidol.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Haloperidol.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Haloperidol.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Haloperidol.Experimental
PromazinePromazine may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Haloperidol.Approved, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Haloperidol.Approved, Investigational
PropafenoneThe serum concentration of Haloperidol can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Haloperidol is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Proparacaine.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Haloperidol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Propoxycaine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Haloperidol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Haloperidol.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Haloperidol.Experimental
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Haloperidol.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Haloperidol.Approved
PSD502The risk or severity of adverse effects can be increased when Haloperidol is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Haloperidol.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Haloperidol.Investigational
PyrimethamineThe metabolism of Haloperidol can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Quazepam.Approved, Illicit
QuetiapineHaloperidol may increase the QTc-prolonging activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Haloperidol.Approved, Investigational
QuinidineHaloperidol may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineHaloperidol may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ramelteon.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Haloperidol.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Haloperidol.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Haloperidol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Haloperidol.Approved, Withdrawn
RepinotanThe metabolism of Repinotan can be decreased when combined with Haloperidol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Haloperidol.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Haloperidol.Approved, Experimental, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Haloperidol.Approved, Investigational
RifabutinThe metabolism of Haloperidol can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Haloperidol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Haloperidol can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Haloperidol.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Haloperidol.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Haloperidol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ritanserin.Investigational
RitobegronHaloperidol may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Haloperidol can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Haloperidol.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Haloperidol.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Haloperidol can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Romifidine.Vet Approved
RopiniroleHaloperidol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Haloperidol.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Haloperidol.Approved
RotigotineHaloperidol may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Haloperidol.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Haloperidol.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Haloperidol.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Haloperidol.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Haloperidol.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Haloperidol.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Haloperidol.Approved
SaquinavirThe metabolism of Haloperidol can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Scopolamine.Approved, Investigational
SecobarbitalThe metabolism of Haloperidol can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Haloperidol.Approved, Investigational, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Haloperidol.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sepranolone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Haloperidol.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Haloperidol.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Haloperidol.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Haloperidol.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Haloperidol can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Haloperidol.Approved
SiltuximabThe serum concentration of Haloperidol can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Haloperidol can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Haloperidol.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Haloperidol.Approved
SorafenibThe metabolism of Haloperidol can be decreased when combined with Sorafenib.Approved, Investigational
SotalolHaloperidol may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Haloperidol.Experimental
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Haloperidol.Investigational
St. John's WortThe serum concentration of Haloperidol can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Haloperidol can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Haloperidol can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Haloperidol can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Haloperidol.Approved
SulfisoxazoleThe metabolism of Haloperidol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Haloperidol.Approved, Investigational
SulpirideHaloperidol may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Haloperidol.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Haloperidol.Approved, Withdrawn
SuvorexantHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Haloperidol.Experimental
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Haloperidol resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Haloperidol.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Haloperidol.Investigational
TasimelteonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Haloperidol.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Haloperidol.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Haloperidol can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinHaloperidol may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Haloperidol can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol.Approved, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Haloperidol.Experimental
Tenofovir disoproxilThe metabolism of Haloperidol can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Haloperidol.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Haloperidol.Vet Approved
TerbinafineThe metabolism of Haloperidol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Haloperidol.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Haloperidol.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Haloperidol.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Haloperidol.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Haloperidol.Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Haloperidol.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetrodotoxin.Investigational
ThalidomideHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Haloperidol can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Haloperidol.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tiapride.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Haloperidol.Approved
TicagrelorThe metabolism of Haloperidol can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Haloperidol can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tilidine.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Haloperidol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Haloperidol.Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Haloperidol.Approved
TipranavirThe metabolism of Haloperidol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
TocilizumabThe serum concentration of Haloperidol can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Haloperidol can be decreased when combined with Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Haloperidol.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Haloperidol.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Haloperidol.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Haloperidol.Approved
TopiramateThe metabolism of Haloperidol can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Haloperidol can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Haloperidol.Approved, Investigational
ToremifeneHaloperidol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Haloperidol.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Haloperidol.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Haloperidol.Approved, Investigational
TranylcypromineThe metabolism of Haloperidol can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Haloperidol.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triazolam.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Haloperidol.Experimental
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe metabolism of Haloperidol can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Haloperidol.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triprolidine.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Haloperidol.Investigational
TriptorelinTriptorelin may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Haloperidol.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Haloperidol.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Haloperidol.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Haloperidol is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Haloperidol can be decreased when combined with Valsartan.Approved, Investigational
VandetanibHaloperidol may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Haloperidol.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Haloperidol.Approved
VenlafaxineThe metabolism of Haloperidol can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Veralipride.Experimental
VerapamilThe metabolism of Haloperidol can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Haloperidol.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Haloperidol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Haloperidol.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Haloperidol.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Haloperidol.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Haloperidol.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Haloperidol is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Haloperidol can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Haloperidol.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Xylazine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Haloperidol.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Haloperidol can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Haloperidol.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zaleplon.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Haloperidol.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ziconotide.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Haloperidol.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zimelidine.Withdrawn
ZiprasidoneHaloperidol may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Haloperidol.Approved, Investigational
ZolpidemHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Haloperidol.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Haloperidol can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolHaloperidol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation, limit caffeine intake. Avoid alcohol.

References

Synthesis Reference
US3438991
General References
  1. Niemegeers CJ, Laduron PM: Pharmacology and biochemistry of haloperidol. Proc R Soc Med. 1976;69 suppl 1:3-8. [PubMed:14331]
  2. Gelders YG: Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate. Int Clin Psychopharmacol. 1986 Jul;1 Suppl 1:1-11. [PubMed:3559159]
  3. Kudo S, Ishizaki T: Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999 Dec;37(6):435-56. doi: 10.2165/00003088-199937060-00001. [PubMed:10628896]
  4. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  5. Haloperidol [Link]
  6. Haloperidol PubMed Health [Link]
  7. Haloperidol PubChem [Link]
  8. Epocrates, Haloperidol [Link]
  9. Treatment mechanisms: traditional and new antipsychotic drugs [Link]
  10. Haloperidol PDR [Link]
  11. Schizophrenia: More dopamine, more D2 receptors [Link]
  12. Clinical pharmacology of atypical antipsychotics: an update [Link]
  13. Mechanism of Action of Antipsychotics, Haloperidol and Olanzapine in vitro [Link]
  14. Haloperidol Overview [Link]
  15. Haloperidol, Mental Retardation and Extrapyramidal Symptoms [Link]
  16. Haloperidol, revised [Link]
  17. Haldol Decanoate [Link]
External Links
Human Metabolome Database
HMDB0014645
KEGG Drug
D00136
KEGG Compound
C01814
PubChem Compound
3559
PubChem Substance
46508794
ChemSpider
3438
BindingDB
21398
ChEBI
5613
ChEMBL
CHEMBL54
Therapeutic Targets Database
DAP000313
PharmGKB
PA449841
IUPHAR
86
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Haloperidol
ATC Codes
N05AD01 — Haloperidol
AHFS Codes
  • 28:16.08.08 — Butyrophenones
FDA label
Download (169 KB)
MSDS
Download (73.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnTreatmentNausea / Vomiting1
1Active Not RecruitingPreventionNicotine Dependence1
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentPsychosis1
1Unknown StatusNot AvailableHealthy Volunteers / Pharmacogenetics1
1, 2Not Yet RecruitingTreatmentAcute Polymorphic Psychotic Disorder With Symptoms of Schizophrenia / Schizophrenia and Disorders With Psychotic Features1
2Active Not RecruitingSupportive CareAdvanced Cancers1
2CompletedDiagnosticPathological Gambling1
2CompletedTreatmentAcute Agitation / Delirium / Intensive Care / Respiration, Artificial / Ventilator Weaning1
2CompletedTreatmentCognition Disorders / Delirium1
2CompletedTreatmentCritical Illness / Delirium1
2CompletedTreatmentSchizophrenic Disorders1
2Not Yet RecruitingTreatmentKetamine / Violent Aggressive Behavior1
2, 3CompletedTreatmentAcute Agitation1
2, 3CompletedTreatmentAffective Disorders1
2, 3RecruitingTreatmentMalignant Neoplasms of Independent (Primary) Multiple Sites1
3CompletedPreventionHip Fractures / Post-Operative Delirium1
3CompletedPreventionPostoperative Confusion1
3CompletedTreatmentAcute Agitation / Schizoaffective Disorders / Schizophrenic Disorders1
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentBipolar Disorder (BD)2
3CompletedTreatmentDelirium1
3CompletedTreatmentPsychomotor Agitation1
3CompletedTreatmentSchizophrenic Disorders4
3RecruitingTreatmentDelirium / Impaired Cognition / Long Term Psychologic Disorders1
3RecruitingTreatmentHypoactive Delirium1
3RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentConfusion and disorientation / Delirium / Postoperative / Psychomotor1
3TerminatedTreatmentDelirium3
3TerminatedTreatmentNausea / Neoplasms1
3Unknown StatusTreatmentPsychosis Nos/Other1
3WithdrawnTreatmentSchizophrenic Disorders1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4Active Not RecruitingTreatmentSchizophrenic Disorders1
4CompletedNot AvailableSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedBasic SciencePsychosis / Schizophrenic Disorders1
4CompletedPreventionCognitive Impairments / Delirium / Depression / Feeling Anxious / Post-Traumatic Stress Disorder (PTSD)1
4CompletedPreventionDelirium1
4CompletedSupportive CareDelirium / Stem Cell Transplant Complications1
4CompletedTreatmentAcute Agitation1
4CompletedTreatmentAcute Agitation / Alzheimer's Disease (AD) / Psychosis1
4CompletedTreatmentHeadaches / Migraine Disorders1
4CompletedTreatmentKetamine Induced Agitation1
4CompletedTreatmentMigrainous Headache / Nausea / Restlessness1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders3
4CompletedTreatmentSchizophrenic Disorders5
4CompletedTreatmentSubsyndromal Delirium1
4Not Yet RecruitingTreatmentFirst Labor Stage / Humanizing Deliver / Labor Onset / Labour Pain / Natural Childbirth / Parturition1
4RecruitingPreventionDelirium2
4RecruitingPreventionPostoperative Delirium1
4RecruitingTreatmentAcute Agitation, Behavioural Emergency1
4RecruitingTreatmentAcute Agitation / Behavioural Emergency1
4RecruitingTreatmentCannabis Use Disorders1
4RecruitingTreatmentDelirium1
4SuspendedTreatmentHyperactive Delirium / Mixed Delirium1
4SuspendedTreatmentMigrainous Headache1
4TerminatedTreatmentBipolar Disorder (BD)1
4TerminatedTreatmentGastroparesis1
4TerminatedTreatmentHaloperidol Causing Adverse Effects in Therapeutic Use / Lorazepam Causing Adverse Effects in Therapeutic Use / Loxapine Causing Adverse Effects in Therapeutic Use / Psychomotor Agitation1
4TerminatedTreatmentSchizophrenic Disorders3
4Unknown StatusTreatmentAcute Schizophrenia1
4Unknown StatusTreatmentSchizophrenia, First-Episode1
4WithdrawnTreatmentAcute Agitation1
Not AvailableActive Not RecruitingNot AvailableSchizophrenic Disorders1
Not AvailableActive Not RecruitingTreatmentSchizophrenia Relapse1
Not AvailableCompletedNot AvailableAcidosis, Respiratory / Movement Disorders1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableDyslipidemias / Insulin Resistance2
Not AvailableCompletedNot AvailableNormal Volunteers1
Not AvailableCompletedNot AvailablePsychomotor Agitation2
Not AvailableCompletedNot AvailableQT Interval Prolongation1
Not AvailableCompletedPreventionGynecological Disease1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedScreeningBMI >30 kg/m2 / Diabetes Mellitus (DM) / Metabolic Syndromes1
Not AvailableCompletedSupportive CareFocus of Study: Absorption of the Three Components in the Topical ABH Gel in Healthy Volunteers, and Determine if There Are Any Adverse Effects / Healthy Volunteers1
Not AvailableCompletedSupportive CareNausea / Vomiting1
Not AvailableCompletedSupportive CarePatient Noncompliance1
Not AvailableCompletedTreatmentCancer, Advanced / Delirium1
Not AvailableCompletedTreatmentCognitive Impairments / Delirium1
Not AvailableCompletedTreatmentPost Streptococcal Movement Disorder / Sydenham Chorea1
Not AvailableCompletedTreatmentPsychomotor Agitation1
Not AvailableCompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
Not AvailableCompletedTreatmentSchizophrenic Disorders7
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableAdverse Drug Effect of Antipsychotics and Neuroleptics / Efficacy / Individualed Opitmal Therapy / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1
Not AvailableTerminatedTreatmentAcute Agitation / Delirium1
Not AvailableUnknown StatusTreatmentAcute Agitation1

Pharmacoeconomics

Manufacturers
  • Ortho mcneil pharmaceutical
  • Ortho mcneil pharmaceutical inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Lederle laboratories div american cyanamid co
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Purepac pharmaceutical co
  • Quantum pharmics ltd
  • Roxane laboratories inc
  • Royce laboratories inc
  • Sandoz inc
  • Scs pharmaceuticals
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Ortho mcneil janssen pharmaceutical inc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Alpharma uspd inc
  • Morton grove pharmaceuticals inc
  • Pharmaceutical assoc inc div beach products
  • Silarx pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Ortho mcneil janssen pharmaceuticals inc
  • Abraxis pharmaceutical products
  • Akorn strides llc
  • Gland pharma ltd
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Solopak laboratories inc
  • Actavis mid atlantic llc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • APP Pharmaceuticals
  • APPD
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Boca Pharmacal
  • Cadila Healthcare Ltd.
  • Cardinal Health
  • Coupler Enterprises Inc.
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Janssen-Ortho Inc.
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Mckesson Corp.
  • McNeil Laboratories
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Novex Pharma
  • Nucare Pharmaceuticals Inc.
  • OMJ Pharmaceuticals
  • Ortho Mcneil Janssen Pharmaceutical Inc.
  • Ortho-McNeil-Janssen Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmacia Inc.
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sandoz
  • Sicor Pharmaceuticals
  • Silarx Pharmaceuticals
  • Southwood Pharmaceuticals
  • Superior Pharmeceuticals
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
InjectionIntramuscular5 mg/1
InjectionIntramuscular5 mg/mL
Injection, solutionIntramuscular5 mg/mL
SolutionOral2 mg/mL
Solution, concentrateOral2 mg/mL
TabletOral.5 mg/1
TabletOral0.5 mg/1
TabletOral1 mg/1
TabletOral10 mg/1
TabletOral2 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
InjectionIntramuscular100 mg/mL
InjectionIntramuscular50 mg/mL
Injection, solutionIntramuscular100 mg/mL
Injection, solutionIntramuscular50 mg/mL
Injection, solutionIntramuscular500 mg/5mL
LiquidIntramuscular50 mg
LiquidIntramuscular5 mg
SolutionIntramuscular5 mg
LiquidIntramuscular100 mg
SolutionOral2 mg
TabletOral.5 mg
TabletOral10 mg
TabletOral1 mg
TabletOral2 mg
TabletOral5 mg
SolutionIntramuscular100 mg
SolutionIntramuscular50 mg
TabletOral0.5 mg
TabletOral20 mg
Prices
Unit descriptionCostUnit
Haloperidol Decanoate 100 mg/ml Solution 5ml Vial257.14USD vial
Haldol decanoate 100 ampul107.77USD ml
Haldol decanoate 50 ampul56.53USD ml
Haloperidol dec 100 mg/ml vial29.85USD ml
Haloperidol powder21.42USD g
Haloperidol dec 50 mg/ml vial17.71USD ml
Haloperidol La 100 mg/ml15.42USD ml
Haldol 5 mg/ml ampul13.4USD ml
Haloperidol La 50 mg/ml7.71USD ml
Haloperidol 5 mg/ml4.73USD ml
Haloperidol lac 5 mg/ml vial3.54USD ml
Haloperidol 20 mg tablet2.81USD tablet
Haloperidol 10 mg tablet1.46USD tablet
Haloperidol 5 mg tablet0.8USD tablet
Novo-Peridol 20 mg Tablet0.66USD tablet
Haloperidol 2 mg tablet0.49USD tablet
Haloperidol lac 2 mg/ml conc0.45USD ml
Haloperidol 1 mg tablet0.36USD tablet
Haloperidol 0.5 mg tablet0.25USD tablet
Pernox scrub cleanser0.18USD g
Apo-Haloperidol 5 mg Tablet0.16USD tablet
Novo-Peridol 5 mg Tablet0.16USD tablet
Apo-Haloperidol 10 mg Tablet0.14USD tablet
Novo-Peridol 10 mg Tablet0.14USD tablet
Apo-Haloperidol 2 mg Tablet0.11USD tablet
Novo-Peridol 2 mg Tablet0.11USD tablet
Apo-Haloperidol 1 mg Tablet0.06USD tablet
Novo-Peridol 1 mg Tablet0.06USD tablet
Apo-Haloperidol 0.5 mg Tablet0.04USD tablet
Novo-Peridol 0.5 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)148MSDS
water solubility14 mg/L (at 25 °C)https://pubchem.ncbi.nlm.nih.gov/compound/haloperidol
logP4.3https://pubchem.ncbi.nlm.nih.gov/compound/haloperidol
logS-4.43https://pubchem.ncbi.nlm.nih.gov/compound/haloperidol
pKa8.66EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.00446 mg/mLALOGPS
logP3.7ALOGPS
logP3.66ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)13.96ChemAxon
pKa (Strongest Basic)8.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity102.59 m3·mol-1ChemAxon
Polarizability39.15 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9465
Caco-2 permeable+0.6023
P-glycoprotein substrateSubstrate0.6673
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8137
Renal organic cation transporterInhibitor0.6058
CYP450 2C9 substrateNon-substrate0.8355
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.5796
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9207
CYP450 2D6 inhibitorInhibitor0.9197
CYP450 2C19 inhibitorNon-inhibitor0.9248
CYP450 3A4 inhibitorInhibitor0.6899
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7933
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8769
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.4367 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5
hERG inhibition (predictor II)Inhibitor0.7474
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0079-3290000000-cc6a990404ba7b9452a8
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0009000000-cdfdd91dd85d2c1cbd3d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00or-0409000000-d542c35143556b83b87a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0900000000-3985dded029c89448ebe
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01b9-0900000000-720c0a4f1130b4237f32
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0900000000-772a799ebb3b949cef0c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0009000000-21c8918254235e561129
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0904000000-8c97cb39f9680dd91378
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01b9-0900000000-571a03ebb5faa3e5cd63
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0900000000-62e233fd691121c78e96
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0900000000-91bf80d34ef94ed709f0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0900000000-46ef29917220709863a4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-3900000000-26f391756d439f7dbfc8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00b9-9600000000-404fc399b40cfb560a99
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00b9-9100000000-8779758823471091566a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-1619000000-27aa28ad7f91429f5ae7
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0609000000-f7c623630d33dbd89e2b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01b9-3911000000-78d5b34044714e81aec3
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Phenylpiperidines / Phenylbutylamines / Butyrophenones / Aryl alkyl ketones / Benzoyl derivatives / Aralkylamines / Fluorobenzenes / Chlorobenzenes / Aryl chlorides / Aryl fluorides
show 9 more
Substituents
Alkyl-phenylketone / Phenylpiperidine / Butyrophenone / Phenylbutylamine / Benzoyl / Aryl alkyl ketone / Aralkylamine / Chlorobenzene / Fluorobenzene / Halobenzene
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, tertiary alcohol, monochlorobenzenes, aromatic ketone, hydroxypiperidine (CHEBI:5613)

Targets

Details
1. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, Cox BF, Brioni JD, Moreland RB: Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav. 2005 May;81(1):211-9. [PubMed:15894081]
  2. Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore GJ, Bolognani F, Lauriello J, Perrone-Bizzozero N, Galloway MP: Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology. 2006 Apr;31(4):751-6. [PubMed:16132064]
  3. Ishiwata K, Oda K, Sakata M, Kimura Y, Kawamura K, Oda K, Sasaki T, Naganawa M, Chihara K, Okubo Y, Ishii K: A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors. Ann Nucl Med. 2006 Oct;20(8):569-73. [PubMed:17134027]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  5. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. [PubMed:16730699]
  6. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
  7. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
  8. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630]
Details
2. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999 Nov;56(5):989-96. [PubMed:10531405]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic site...
Gene Name
GRIN2B
Uniprot ID
Q13224
Uniprot Name
Glutamate receptor ionotropic, NMDA 2B
Molecular Weight
166365.885 Da
References
  1. Hattori K, Uchino S, Isosaka T, Maekawa M, Iyo M, Sato T, Kohsaka S, Yagi T, Yuasa S: Fyn is required for haloperidol-induced catalepsy in mice. J Biol Chem. 2006 Mar 17;281(11):7129-35. Epub 2006 Jan 10. [PubMed:16407246]
  2. Zhuravliova E, Barbakadze T, Natsvlishvili N, Mikeladze DG: Haloperidol induces neurotoxicity by the NMDA receptor downstream signaling pathway, alternative from glutamate excitotoxicity. Neurochem Int. 2007 Jun;50(7-8):976-82. Epub 2006 Nov 7. [PubMed:17092607]
  3. Gu WH, Yang S, Shi WX, Zhen XC, Jin GZ: Effects of (-)-stepholidine on NMDA receptors: comparison with haloperidol and clozapine. Acta Pharmacol Sin. 2007 Jul;28(7):953-8. [PubMed:17588330]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  5. Steinmetz RD, Fava E, Nicotera P, Steinhilber D: A simple cell line based in vitro test system for N-methyl-D-aspartate (NMDA) receptor ligands. J Neurosci Methods. 2002 Jan 15;113(1):99-110. [PubMed:11741727]
  6. Sinor JD, Du S, Venneti S, Blitzblau RC, Leszkiewicz DN, Rosenberg PA, Aizenman E: NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurons in vitro. J Neurosci. 2000 Dec 1;20(23):8831-7. [PubMed:11102491]
  7. Gallagher MJ, Huang H, Lynch DR: Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions. J Neurochem. 1998 May;70(5):2120-8. [PubMed:9572299]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
Details
5. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inverse agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
  2. Tuppurainen H, Kuikka JT, Viinamaki H, Husso M, Tiihonen J: Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry Clin Neurosci. 2009 Aug;63(4):529-37. doi: 10.1111/j.1440-1819.2009.01982.x. Epub 2009 May 22. [PubMed:19496999]
  3. Tadori Y, Forbes RA, McQuade RD, Kikuchi T: Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol. 2008 Nov 12;597(1-3):27-33. doi: 10.1016/j.ejphar.2008.09.008. Epub 2008 Sep 20. [PubMed:18831971]
  4. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY: Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology. 2005 Dec;30(12):2283-9. [PubMed:16123775]
  5. Malmberg, Mikaels, Mohell N: Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding. J Pharmacol Exp Ther. 1998 Apr;285(1):119-26. [PubMed:9536001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Neuropeptide receptor activity
Specific Function
Receptor for melanin-concentrating hormone, coupled to both G proteins that inhibit adenylyl cyclase and G proteins that activate phosphoinositide hydrolysis.
Gene Name
MCHR1
Uniprot ID
Q99705
Uniprot Name
Melanin-concentrating hormone receptor 1
Molecular Weight
45962.185 Da
References
  1. Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J, Antel J: No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. Epub 2006 Sep 19. [PubMed:16983399]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Monoamine transmembrane transporter activity
Specific Function
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles...
Gene Name
SLC18A2
Uniprot ID
Q05940
Uniprot Name
Synaptic vesicular amine transporter
Molecular Weight
55712.075 Da
References
  1. Gonzalez AM, Walther D, Pazos A, Uhl GR: Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res. 1994 Mar;22(1-4):219-26. [PubMed:7912402]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Tateishi T, Watanabe M, Kumai T, Tanaka M, Moriya H, Yamaguchi S, Satoh T, Kobayashi S: CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci. 2000 Nov 3;67(24):2913-20. [PubMed:11133003]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  2. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. [PubMed:10688273]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM: Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9. [PubMed:12584149]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-e2 9-reductase activity
Specific Function
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. ...
Gene Name
CBR1
Uniprot ID
P16152
Uniprot Name
Carbonyl reductase [NADPH] 1
Molecular Weight
30374.73 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  3. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686]

Drug created on June 13, 2005 07:24 / Updated on July 13, 2018 01:00